AR and pachyonychia congenita: Despite considerable efforts in the development of new androgen/androgen receptor (AR) antagonists, such as abiraterone and enzalutamide, current treatments often fail to achieve long-term efficacy and most patients relapse and develop castrate-resistant PC (CRPC), frequently characterized by metastatic spreading3.